JPS58126814A - トキソプラズマ免疫確認用の新規な抗原およびその製造方法 - Google Patents
トキソプラズマ免疫確認用の新規な抗原およびその製造方法Info
- Publication number
- JPS58126814A JPS58126814A JP57217930A JP21793082A JPS58126814A JP S58126814 A JPS58126814 A JP S58126814A JP 57217930 A JP57217930 A JP 57217930A JP 21793082 A JP21793082 A JP 21793082A JP S58126814 A JPS58126814 A JP S58126814A
- Authority
- JP
- Japan
- Prior art keywords
- toxoplasma
- antigen
- culture
- serum
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 title claims description 46
- 102000036639 antigens Human genes 0.000 title claims description 46
- 108091007433 antigens Proteins 0.000 title claims description 46
- 230000036039 immunity Effects 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 201000005485 Toxoplasmosis Diseases 0.000 title description 2
- 241000223996 Toxoplasma Species 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 239000002609 medium Substances 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- 241000700198 Cavia Species 0.000 claims description 9
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 241000223997 Toxoplasma gondii Species 0.000 claims description 9
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 230000009610 hypersensitivity Effects 0.000 claims description 9
- 244000309466 calf Species 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 210000002421 cell wall Anatomy 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 238000012790 confirmation Methods 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 210000001840 diploid cell Anatomy 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 6
- 238000011146 sterile filtration Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000009589 serological test Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 241000922351 Anoma Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8123565 | 1981-12-17 | ||
| FR8123565A FR2518407A1 (fr) | 1981-12-17 | 1981-12-17 | Nouvel antigene pour la recherche de l'immunite toxoplasmique et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS58126814A true JPS58126814A (ja) | 1983-07-28 |
Family
ID=9265121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57217930A Pending JPS58126814A (ja) | 1981-12-17 | 1982-12-14 | トキソプラズマ免疫確認用の新規な抗原およびその製造方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0082745B1 (enExample) |
| JP (1) | JPS58126814A (enExample) |
| AR (1) | AR228806A1 (enExample) |
| AT (1) | ATE14274T1 (enExample) |
| AU (1) | AU554541B2 (enExample) |
| CA (1) | CA1206904A (enExample) |
| DE (1) | DE3264792D1 (enExample) |
| ES (1) | ES8308485A1 (enExample) |
| FI (1) | FI71165C (enExample) |
| FR (1) | FR2518407A1 (enExample) |
| NO (1) | NO824242L (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2564731B1 (fr) * | 1984-05-28 | 1986-10-10 | Ambroise Thomas Pierre | Nouvelles fractions exo-antigeniques toxoplasmiques, leur procede de preparation et leur application a la recherche de l'immunite toxoplasmique chez l'homme par tests cutanes |
| FR2618680B1 (fr) * | 1987-07-31 | 1990-05-11 | Pasteur Institut | Antigenes d'excretion-secretion specifiques de toxoplasma gondii, leurs produits d'expression, leur procede d'obtention et leurs applications diagnostiques et prophylactiques |
| FR2625099B1 (fr) * | 1987-12-24 | 1991-06-14 | Transgene Sa | Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose |
| WO2006094665A1 (en) | 2005-03-08 | 2006-09-14 | Kenton Srl | Chimeric recombinant antigens of toxoplasma gondii |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5444016A (en) * | 1977-09-13 | 1979-04-07 | Nippon Touketsu Kansou Kenkiyu | Latex coagulation and reaction reagent for detecting toxoplasma antibody and production thereof |
| JPS5739350A (en) * | 1980-05-20 | 1982-03-04 | Biomuriyoo | Preparation of toxoplasma antigen |
-
1981
- 1981-12-17 FR FR8123565A patent/FR2518407A1/fr active Granted
-
1982
- 1982-12-02 DE DE8282402197T patent/DE3264792D1/de not_active Expired
- 1982-12-02 EP EP82402197A patent/EP0082745B1/fr not_active Expired
- 1982-12-02 AT AT82402197T patent/ATE14274T1/de active
- 1982-12-10 AR AR291563A patent/AR228806A1/es active
- 1982-12-10 AU AU91404/82A patent/AU554541B2/en not_active Ceased
- 1982-12-13 ES ES518127A patent/ES8308485A1/es not_active Expired
- 1982-12-14 JP JP57217930A patent/JPS58126814A/ja active Pending
- 1982-12-14 FI FI824280A patent/FI71165C/fi not_active IP Right Cessation
- 1982-12-16 CA CA000417915A patent/CA1206904A/en not_active Expired
- 1982-12-16 NO NO824242A patent/NO824242L/no unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5444016A (en) * | 1977-09-13 | 1979-04-07 | Nippon Touketsu Kansou Kenkiyu | Latex coagulation and reaction reagent for detecting toxoplasma antibody and production thereof |
| JPS5739350A (en) * | 1980-05-20 | 1982-03-04 | Biomuriyoo | Preparation of toxoplasma antigen |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3264792D1 (en) | 1985-08-22 |
| EP0082745B1 (fr) | 1985-07-17 |
| ATE14274T1 (de) | 1985-08-15 |
| CA1206904A (en) | 1986-07-02 |
| FI71165B (fi) | 1986-08-14 |
| ES518127A0 (es) | 1983-09-01 |
| FR2518407B1 (enExample) | 1984-05-04 |
| FI824280L (fi) | 1983-06-18 |
| NO824242L (no) | 1983-06-20 |
| EP0082745A1 (fr) | 1983-06-29 |
| ES8308485A1 (es) | 1983-09-01 |
| FR2518407A1 (fr) | 1983-06-24 |
| AU554541B2 (en) | 1986-08-28 |
| FI71165C (fi) | 1986-11-24 |
| AU9140482A (en) | 1983-06-23 |
| FI824280A0 (fi) | 1982-12-14 |
| AR228806A1 (es) | 1983-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Greene et al. | Mechanisms of regulation of cell-mediated immune responses: I. Effect of the route of immunization with TNP-coupled syngeneic cells on the induction and suppression of contact sensitivity to picryl chloride | |
| Provost et al. | Etiologic relationship of marmoset-propagated CR326 hepatitis A virus to hepatitis in man | |
| EA003182B1 (ru) | Универсальная плазма крови | |
| JPH04502410A (ja) | ウイルスの生産およびワクチン使用のためのウイルスエンベロープタンパク質の精製 | |
| RU2447898C2 (ru) | Вакцина ipv-dpt | |
| De Gast et al. | Specific lymphocyte stimulation by purified, heat-inactivated hepatitis-B antigen | |
| JPS58126814A (ja) | トキソプラズマ免疫確認用の新規な抗原およびその製造方法 | |
| EP0253313B1 (en) | Process for heat treating chemically unmodified gamma-globulin | |
| JPH02138130A (ja) | 重合されたアレルゲンの製造方法 | |
| Laufs | Immunisation of marmoset monkeys with a killed oncogenic herpesvirus | |
| Lepow et al. | Eight-year serologic evaluation of Edmonston live measles vaccine | |
| JPS6242887B2 (enExample) | ||
| BR9407182A (pt) | Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado | |
| JPH01502978A (ja) | 免疫原性の低下及び免疫寛容の誘導のための方法 | |
| CN102816237A (zh) | 抗d人免疫球蛋白的制备方法 | |
| Thorbecke et al. | Effect of rabbit interferon on immune responses | |
| CN102813915B (zh) | 药物诱导的亚细胞结构疫苗及其制备方法 | |
| JPH0751513B2 (ja) | Ａ型肝炎ワクチン | |
| Kroon et al. | Abortive and subclinical poliomyelitis in a family during the 1992 epidemic in The Netherlands | |
| CN1893960B (zh) | 从非高加索人血浆生产的普遍适用的病毒灭活血浆 | |
| Bergstrand et al. | Antigen-induced release of histamine from rat tissues in vitro: Dissociation in development of serosal mast cell, lung tissue, and tracheal tissue response capacity | |
| Johnson | Status of arenavirus vaccines and their application | |
| Furesz et al. | Vaccination against measles in the Canadian Arctic | |
| Hilleman et al. | Infectious hepatitis (hepatitis A) research in nonhuman primates | |
| Umer et al. | Allogenic Stem Cell Transplantation and COVID-19 Antibodies: Mechanistic Insights and Recipient Concerns |